What they found (summary): Development of Melanotan II as a cutaneous drug failed due to the combination of side effects Bifurcation into more selective derivatives was both scientifically and commercially successful PT-141 Bremelanotide (Vyleesi, 2019) Melanotan I Afamelanotide (Scenesse, 2014) Underground use of Melanotan II is safety-problematic Why it matters: This is the definitive historical review by the founders of the field
doi:10.1038/nrendo.2017.151 2
Food and Drug Administration approved the medications for chronic weight management in adults with obesity or those who are overweight with at least one weight-related condition, such as high blood pressure, prediabetes or blood vessel disease
Clear dose-response relationships : Longer acetaminophen use correlates with higher attention/focus disorder risk, with strongest evidence linking prenatal NAPQI exposure to attention and behavioral disorders
If your A1C drops quickly or we see early signs of retinopathy worsening, we increase monitoring frequency
What is the standard treatment for malignant schwannoma
